So SSTR2 is expressed very highly and uniformly in meningiomas, so it’s 95% of meningiomas that will have SSTR2 expression. Compared to other agents like somatostatin analogs, which also target SSTR2, the 177-lutetium dotatate doesn’t necessarily influence the pathways or the biological mechanisms within the cell, but it really kind of serves as like a carrier...
So SSTR2 is expressed very highly and uniformly in meningiomas, so it’s 95% of meningiomas that will have SSTR2 expression. Compared to other agents like somatostatin analogs, which also target SSTR2, the 177-lutetium dotatate doesn’t necessarily influence the pathways or the biological mechanisms within the cell, but it really kind of serves as like a carrier. Like the SSTR2 on the meningioma cell kind of binds to the lutetium dotatate, and then the construct gets internalized into the cell. It doesn’t necessarily influence the pathways within the cell, but the radioactivity that’s getting absorbed by the cell radiates the cell from within. And that’s like a fundamentally different mechanism of action compared to other SSTR2-targeted agents.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
